Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 172.34 Delayed Data As of Jan 22 |  +5.59 / +3.35%Today’s Change | 84.97 Today|||52-Week Range 175.41 | +32.60% Year-to-Date |
Latest ALNY News | Press Releases
| 3 Lesser-Known Biotech Stocks that are Surging Jan 20 / StockNews.com - Paid Partner Content | Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy Jan 13 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 166.75 |
| Today’s open | 166.37 |
| Day’s range | 164.03 - 173.30 |
| Volume | 33,632 |
| Average volume (3 months) | 581,049 |
| Market cap | $20.0B |
Data as of 3:59pm ET, 01/22/2021
Growth & Valuation
| Earnings growth (last year) | -7.13% |
| Earnings growth (this year) | +11.46% |
| Earnings growth (next 5 years) | +29.35% |
| Revenue growth (last year) | +193.36% |
| P/E ratio | NM |
| Price/Sales | 57.26 |
| Price/Book | 13.42 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CTLTCatalent Inc | -1.42 | -1.20% |
| INCYIncyte Corp | +3.98 | +4.24% |
| VTRSViatris Inc | +0.12 | +0.69% |
| HZNPHorizon Therapeutics... | +0.29 | +0.37% |
Data as of 4:00pm ET, 01/22/2021
Financials
| Next reporting date | February 11, 2021 |
| EPS forecast (this quarter) | -$1.76 |
| Annual revenue (last year) | $219.8M |
| Annual profit (last year) | -$886.1M |
| Net profit margin | -403.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
